GXO Logistics Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? GXO Logistics Inc trades at $45.88 (market cap $5.33B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 29 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GXO | HNGE | |
|---|---|---|
Market Cap | $5.33B | $8.48B |
Volume | 961,023 | 879,799 |
Sector | Industrials | Health |
52-Week High | $65.59 | $105.14 |
52-Week Low | $44.17 | $31.17 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $10.68B | $8.10B |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $46.50, down 0.21% with neutral technical signals. The company shows strong revenue growth with 2026 revenue reaching $13.6B and net profit margin improving to 0.96%. Recent earnings beats and strategic partnerships in Europe and aerospace sectors demonstrate operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and a $66.67 price target, representing 43% upside potential from current levels.
The stock presents compelling value with attractive valuation metrics including P/S of 0.39x, though elevated P/E of 41.15x reflects growth expectations. Key risks include margin pressure from new business at lower incremental margins and competitive industry dynamics. The improving freight industry outlook and GXO's market leadership position support long-term growth prospects despite near-term execution challenges.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →